Countdown To The Allergan Merger, And More From AbbVie’s Q4 Earnings

 
• By Joseph Haas

Despite Humira’s ex-US sales erosion, AbbVie reports strong launches for Skyrizi and Rinvoq, continued growth for hematological oncology franchise, and boasts it has a thriving R&D engine.

Rockets
Sales are soaring for recent AbbVie launches like Skyrizi, Imbruvica and Venclexta

More from Earnings

More from Business